Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.

Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.

The present invention relates to a clear liquid ophthalmic composition comprising as the active ingredient a Spirulina platensis full extract and suitable liquid carriers and solubilising excipients. The invention also relates to a viscous liquid composition comprising an aqueous extract of spirulina platensis and to the use of said compositions in the treatment of several eye diseases.

The present invention relates to a clear liquid ophthalmic composition comprising as the active ingredient a Spirulina platensis full extract and suitable liquid carriers and solubilising excipients. The invention also relates to a viscous liquid composition comprising an aqueous extract of spirulina platensis and to the use of said compositions in the treatment of several eye diseases.

The present invention relates to a composition, preferably a cosmetic composition, comprising, in an aqueous phase: at least one anti-acne active agent; and hydroxyethylcellulose and at least poly(2-acrylamido 2-methyl propane sulfonic acid),
and uses thereof.

The present invention relates to a composition, preferably a cosmetic composition, comprising, in an aqueous phase: at least one anti-acne active agent; and hydroxyethylcellulose and at least poly(2-acrylamido 2-methyl propane sulfonic acid),
and uses thereof.

The present invention provides compositions comprising an effective amount of a peptide having the amino acid sequence Gly-Gly-(d)Val-(d)Leu-(d)Val-(d)Gln-(d)Pro-Gly (SEQ ID NO: 6) to promote tight junction integrity, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier. The present invention further provides methods of using the larazotide derivative compositions for promoting tight junction integrity in patients in need thereof.

The present invention provides compositions comprising an effective amount of a peptide having the amino acid sequence Gly-Gly-(d)Val-(d)Leu-(d)Val-(d)Gln-(d)Pro-Gly (SEQ ID NO: 6) to promote tight junction integrity, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier. The present invention further provides methods of using the larazotide derivative compositions for promoting tight junction integrity in patients in need thereof.

The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.

The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.